Clinical trial
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
NCT03754309 is registered in ClinicalTrials.gov with Kymab Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
- Lead sponsor
- Kymab Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 13, 2018
- Completion date
- October 8, 2020
- Enrollment
- 89 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.